- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04008355
A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP
August 4, 2023 updated by: AlzProtect SAS
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 on Cerebrospinal Fluid Biomarkers in 36 Patients With Progressive Supranuclear Palsy
A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy.
The patient study duration is 29 weeks including a washout period.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France, 75019
- Hôpital de la Fondation Adolphe de Rothschild
-
-
Hauts De France
-
Lille, Hauts De France, France
- Hôpital Salengro
-
-
Ile-de-France
-
Paris, Ile-de-France, France, 75013
- Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male and female patients with probable or possible PSP
- Patients must be stable with their medication for at least 30 days prior to the inclusion visit.
Exclusion Criteria:
- Any history of clinically significant head trauma or cerebrovascular disease or recent history of substance abuse or alcohol abuse and deemed to be clinically significant by the Investigator.
- History of deep brain stimulator (DBS) surgery other than sham surgery for DBS clinical study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 60mg/day/84 days
Patients randomized in this arm will receive 60 mg of study investigational drug AZP2006 once daily during 84 days.
|
Once daily intake in the morning
|
Experimental: 80mg/day/10 days followed by 50mg/day/74 days
Patients randomized in this arm will receive 80 mg of study investigational drug AZP2006 once daily during 10 days followed by 50 mg of study investigational drug AZP2006 once daily during the next 74 days.
|
Once daily intake in the morning
|
Placebo Comparator: Placebo/84 days
Patients randomized in this arm will receive placebo solution once daily during 84 days.
|
Once daily intake in the morning
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and percentage of patients who prematurely discontinue from the study due to adverse events (AEs)
Time Frame: From Day 1 to Day 180
|
Incidence in pourcentage of treatment-emergent adverse events observed directly by investigator and adverse event spontaneously reported by the patient using concise medical terminology
|
From Day 1 to Day 180
|
The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF
Time Frame: From Day 1 of Day 84 (12 weeks)
|
To determine the Cmax of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks
|
From Day 1 of Day 84 (12 weeks)
|
The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF
Time Frame: From Day 1 of Day 84 (12 weeks)
|
To determine the tmax of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks
|
From Day 1 of Day 84 (12 weeks)
|
The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF
Time Frame: From Day 1 of Day 84 (12 weeks)
|
To determine the kel of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks
|
From Day 1 of Day 84 (12 weeks)
|
The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF
Time Frame: From Day 1 of Day 84 (12 weeks)
|
To determine the Clast of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks
|
From Day 1 of Day 84 (12 weeks)
|
The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF
Time Frame: From Day 1 of Day 84 (12 weeks)
|
To determine the AUC 0-10 of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks
|
From Day 1 of Day 84 (12 weeks)
|
The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF
Time Frame: From Day 1 of Day 84 (12 weeks)
|
To determine the AUC 0-24 of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks
|
From Day 1 of Day 84 (12 weeks)
|
The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF
Time Frame: From Day 1 of Day 84 (12 weeks)
|
To determine the AUC 0-t of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks
|
From Day 1 of Day 84 (12 weeks)
|
The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF
Time Frame: From Day 1 of Day 84 (12 weeks)
|
To determine the t1/2 of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks
|
From Day 1 of Day 84 (12 weeks)
|
The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF
Time Frame: From Day 1 of Day 84 (12 weeks)
|
To determine the tlast of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks
|
From Day 1 of Day 84 (12 weeks)
|
The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF
Time Frame: From Day 1 of Day 84 (12 weeks)
|
To determine the %AUCextra of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks
|
From Day 1 of Day 84 (12 weeks)
|
The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF
Time Frame: From Day 1 of Day 84 (12 weeks)
|
To determine the CL/F of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks
|
From Day 1 of Day 84 (12 weeks)
|
The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF
Time Frame: From Day 1 of Day 84 (12 weeks)
|
To determine the Vd/F of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks
|
From Day 1 of Day 84 (12 weeks)
|
The pharmacokinetics of AZP2006 (12-week treatment period) in plasma, blood, and CSF
Time Frame: From Day 1 of Day 84 (12 weeks)
|
To determine the Ctrough of AZP2006 in plasma, blood, and CSF after single and multiple dose administration, once daily for 12 weeks
|
From Day 1 of Day 84 (12 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Philippe Verwaerde, PhD, AlzProtect SAS
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 22, 2020
Primary Completion (Actual)
July 18, 2022
Study Completion (Estimated)
July 1, 2024
Study Registration Dates
First Submitted
June 18, 2019
First Submitted That Met QC Criteria
July 1, 2019
First Posted (Actual)
July 5, 2019
Study Record Updates
Last Update Posted (Actual)
August 7, 2023
Last Update Submitted That Met QC Criteria
August 4, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Eye Diseases
- Neurologic Manifestations
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Tauopathies
- Cranial Nerve Diseases
- Ocular Motility Disorders
- Paralysis
- Ophthalmoplegia
- Supranuclear Palsy, Progressive
- Pharmaceutical Solutions
Other Study ID Numbers
- AZP2006C04
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Progressive Supranuclear Palsy
-
Novartis PharmaceuticalsActive, not recruitingProgressive Supranuclear Palsy (PSP)Germany, United Kingdom, Canada, United States
-
AbbVieTerminatedProgressive Supranuclear Palsy (PSP)United States, Australia, Canada, Italy, Japan
-
AbbVieCompletedProgressive Supranuclear Palsy (PSP)United States
-
Assistance Publique Hopitaux De MarseilleCompletedProgressive Supranuclear Palsy (PSP)France
-
Oregon Health and Science UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingSupranuclear Palsy, Progressive | Palsy SupranuclearUnited States
-
University of California, San FranciscoNational Institutes of Health (NIH); National Institute on Aging (NIA)Active, not recruitingProgressive Supranuclear Palsy (PSP) | Corticobasal Degeneration (CBD) | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Corticobasal Syndrome (CBS) | Cortical-basal Ganglionic Degeneration (CBGD) | Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)United States, Canada
-
University of California, San FranciscoTau Consortium; CBD SolutionsCompletedProgressive Supranuclear Palsy (PSP) | Corticobasal Degeneration (CBD) | Corticobasal Syndrome (CBS) | Primary Four Repeat Tauopathies (4RT)United States
-
UCB Biopharma SRLCompletedProgressive Supranuclear PalsyBelgium, Germany, Spain, United Kingdom
-
Centre Hospitalier Universitaire de Pointe-a-PitreGroupe Hospitalier Pitie-Salpetriere; University Hospital Center of MartiniqueCompletedProgressive Supranuclear Palsy
-
University of LouisvilleCompletedProgressive Supranuclear PalsyUnited States
Clinical Trials on AZP2006 oral solution
-
Foresee Pharmaceuticals Co., Ltd.CompletedHealthy VolunteersAustralia
-
Crinetics Pharmaceuticals Inc.CompletedHealthy VolunteersAustralia
-
Crinetics Pharmaceuticals Inc.CompletedHealthy VolunteersUnited States
-
Emergent BioSolutionsNational Institute of Allergy and Infectious Diseases (NIAID)TerminatedViral InfectionUnited States
-
IRCCS Burlo GarofoloCompleted
-
Galapagos NVCompletedHealthy | PsoriasisBelgium, Moldova, Republic of, Ukraine
-
Boehringer IngelheimCompletedHIV InfectionsUnited States, Argentina, Brazil, Canada, France, Germany, Italy, Mexico, Puerto Rico, Spain
-
BayerCompleted
-
Shanghai Runshi Pharmaceutical Technology Co., LtdNot yet recruiting